Zhongchao Inc. has obtained the general distribution rights in Mainland China for anti-influenza drug from Indian pharmaceutical firm Natco Pharma. The drug will be introduced to the China market for domestic treatment and prevention of Type A and Type B influenza viruses after the inspection and quarantine.

The anti-influenza drug introduced is Naiditawei, commonly known as Oseltamivir Phosphate Capsules. Oseltamivir Phosphate is approved by FDA in United States for the treatment of flu (influenza Type A and Type B). 

The capsule introduced by Xinjiang Pharmaceutical, one of the China operating entities of Zhongchao Inc., will be available in 75mg, 45mg and 30mg sizes to ensure accurate dosage for patients. The capsule can be used by children, teenagers and adults with Type A and Type B influenza.

In addition, the capsule can be taken with water or other beverages for easier consumption to improve patient compliance. The capsule belongs to Medical Insurance Category B products in China, which is covered by medical insurance, and it is one of the national anti-influenza reserve drugs.

Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, "The registration and listing of foreign drugs in China is an important means to address the clinical needs of patients. With the gradual ease of the pandemic prevention and control policy in China and the superimposed epidemic of Covid-19 and influenza, the demand for related therapeutic drugs is huge. We plan to introduce more batches of oseltamivir phosphate capsules this year."